Gene Logic Launches Human Atlas DataSuite Product
Gene Logic Inc. (Nasdaq:GLGC - news), a leading provider of biological information and bioinformatics products, announced today the formal launch of a new GeneExpress® Suite product, the GeneExpress Human Atlas DataSuite(TM), at the IBC Drug Discovery Technology (DDT) 2001 conference in Boston. The Human Atlas DataSuite(TM), the second product launched from Gene Logic's Atlas Program, is a comprehensive survey of normal human gene expression and is a universal baseline reference source with direct application in therapeutic target screening and prioritization for top-tier pharmaceutical and genomics-based biotechnology companies.
Gene Logic Senior Vice President, Pharmacogenomics Douglas Dolginow, M.D. commented, ``We are committed to providing critical information tools to serve the ongoing research needs of the drug development community as it continues to harness desktop solutions to further improve their drug discovery initiatives at the bench top level. This expanded offering is like a Gray's Anatomy of normal human gene expression, and is expected to become an important genomic desktop reference for pharmaceutical and biotechnology researchers.''
The Human Atlas DataSuite(TM) is initially comprised of several thousand normal human samples and is expected to steadily grow as Gene Logic continues to build its tissue repository. These high-quality, pathologist-reviewed normal samples encompass over 80 normal human organs and tissue types.
Representative human organ systems include circulatory, digestive, endocrine, immune, nervous, reproductive, respiratory, muscular and urinary. The product will also include access to Gene Logic's comprehensive GeneExpress® Software System, the data management and analysis platform, which includes robust mining, visualization and analysis tools. Subscribers to the product will receive regular updates to both the normal human sample content and the bioinformatics tools.
Based upon the quality and comprehensive scope and scale of the normal human samples represented, researchers will be able to use the Human Atlas DataSuite(TM) to formulate a detailed understanding of the mechanisms of normal human biology through large-scale gene expression queries across thousands of normal human samples. The product will also allow for rapid screening and prioritization of potential therapeutic targets through their distribution patterns across normal human samples, as well as leveraging in-house proprietary sequence information or other genomic technologies by identifying normal expression patterns of candidate genes.
The Human Atlas DataSuite(TM) is currently available for subscription. Gene Logic's financial guidance for 2001, provided earlier in the year, reflected the introduction of this new product, and any material financial impact is expected only in future years.
``We are extremely pleased to launch this latest product from our Atlas Program at the DDT conference,'' commented David S. Murray, Senior Vice President, Marketing and Sales for Gene Logic. ``As an extension of the more focused GeneExpress Atlas DataSuite(TM) launched last year, the new Human Atlas DataSuite(TM) constitutes a truly comprehensive view of normal human gene expression and provides a broad and in-depth baseline reference source, which directly addresses the research demands of our pharmaceutical and biotechnology customers.''
Other news from the department research and development
